e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
New targets and modalities for the treatment of asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Dose-FEV1 modeling to support future development of AZD2115, a dual acting bronchodilator for the treatment of COPD
Ulrika Wählby Hamren (Mölndal, Sweden), Ulrika Wählby Hamrén, Fredrik Öhrn, Ajay Aggarwal
Source:
International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Session:
New targets and modalities for the treatment of asthma and COPD
Session type:
Poster Discussion
Number:
2128
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ulrika Wählby Hamren (Mölndal, Sweden), Ulrika Wählby Hamrén, Fredrik Öhrn, Ajay Aggarwal. Dose-FEV1 modeling to support future development of AZD2115, a dual acting bronchodilator for the treatment of COPD. Eur Respir J 2015; 46: Suppl. 59, 2128
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Validation of a new inhaled therapeutic algorithm for the stable COPD patient: The COPD easy treatment project
Source: International Congress 2015 – Management of COPD and other respiratory diseases in primary care
Year: 2015
Lung function, symptoms and prescription of inhaled steroids and long acting β2 agonists in patients managed by an integrated COPD team
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Comparison of protective effect of bronchodilators in COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
The influence of type of inhalation device on adherence of COPD patients to inhaled medication
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and COPD: A preference study
Source: International Congress 2016 – Kaleidoscope of respiratory nursing
Year: 2016
LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016
Onbrace: A real-life evaluation of indacaterol maintenance treatment for COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Distribution and outcomes of the new Spanish phenotype-based guideline for COPD
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Effects of pharmacist interventions to inhalation medication adherence and lung functions in COPD patients at one stop service clinic
Source: International Congress 2014 – COPD exacerbations
Year: 2014
What is the best biomarker of COPD stability?
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Combination therapy versus separate therapy in real-life primary care asthma patients
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015
Differences in adherence to common inhaled medications in COPD
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Effect of breathing parameters on lung dose in case of two combination drugs used in asthma and COPD therapy
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
A new clinically relevant method of calculating adherence
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Optimal adherence with inhaled corticosteroids is related to better health status
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015
The effectiveness of anti-inflammatory therapy for chronic obstructive pulmonary disease complicated by ischemic heart disease (new medication - new opportunities)
Source: International Congress 2014 – Comorbidities
Year: 2014
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept